The pharmaceutical industry continues to undergo radical transformation driven by artificial intelligence (AI), which is playing an increasingly central role in drug research and development (R&D). Sanofi, a major player, exemplifies this trend by integrating AI to optimize drug target discovery. Simultaneously, AI is revolutionizing drug repurposing, promising significant reductions in costs and development timelines. This dynamic is reinforced by strategic collaborations, such as the one between Pfizer and an Austrian institute, aimed at developing innovative AI models. However, these advancements come with regulatory and ethical challenges, necessitating the rapid adaptation of legislative frameworks.
Débloquez l'Analyse Complète
Accédez instantanément à nos insights exclusifs générés par IA, basés sur l'agrégation de centaines de sources sectorielles.
